Center for Global Research Data

A pooled analysis of the efficacy and tolerability of tolterodine for the treatment of Overactive Bladder (OAB) in patients over the age of 65 years of age

Lead Investigator: Adrian Wagg, University of Alberta
Title of Proposal Research: A pooled analysis of the efficacy and tolerability of tolterodine for the treatment of Overactive Bladder (OAB) in patients over the age of 65 years of age
Vivli Data Request: 5436
Funding Source: None
Potential Conflicts of Interest: Dr. Wagg or his institution has received monies for any of research, speaker honoraria, or consultancy from Astellas Pharma, Essity Health and Hygiene AB, Pierre Fabre Medicaments, Pfizer Corp. His wife is an employee of Pfizer Canada in an unrelated business area.

Summary of the Proposed Research:

Overactive bladder (OAB) is a common bladder condition which leads to a troublesome and urgent need to visit the washroom and often leads to accidental leakage of urine. Although not a normal part of ageing, incontinence is more common in older people, and two of every three people with OAB are over the age of 65. OAB causes much embarrassment and distress, and leads to an increased risk of falls and depression. OAB is treatable, usually by managing fluid intake and by a method called bladder retraining. However, many people do not respond to this and require treatment with medicines. There are a number of these available but there is limited evidence of their effect on older people. This study will look at the effect of one medicine called tolterodine. The study will examine all of the available evidence from clinical trials which involved both older and younger patients treated with tolterodine and dummy medicines and pull it together to provide prescribing clinical staff with the best evidence for treatment and safety of tolterodine in older people. We will use a technique called pooled analysis to combine the results of several trials into one larger trial, which will allow us to make better and more accurate estimates of how well this medicine works in older people than the individual trials alone do.

Requested Studies:

Tolterodine and Tamsulosin for Treatment of Men With Lower Urinary Tract Symptoms and Overactive Bladder
Data Contributor: Pfizer Inc.
Study ID: NTC00147654

Effects of tolterodine ER on patient-reported outcomes in sexually active women with overactive bladder and urgency urinary incontinence
Data Contributor: Pfizer Inc.
Study ID: NCT00143481

Pharmacia study: A6121087 Protocol ID: 98-TOCR-007
Data Contributor: Pfizer Inc.
Study ID: A6121087 – 98-TOCR-007